View Document Preview and Link Document Date: 2014-04-03 18:36:05 Open Document File Size: 342,32 KB Share Result on Facebook
City Horsham / Cambridge / / Company Actavis / Celltrion Healthcare Co. Ltd. / Johnson & Johnson / Celltrion Inc. / Defendant Janssen Biotech Inc. / Amgen / Boehringer Ingelheim / Biogen Idec / Merck / Centocor Inc. / Novartis/Sandoz / Janssen Biotech Inc. / Samsung / / Country United States / Korea / South Korea / / Currency USD / / Event FDA Phase / Patent Issuance / Patent Filing / Product Release / / Facility New York University / / IndustryTerm innate protein‐making machinery / biological product / biopharmaceutical medicines / manufacturing platform / pharmaceutical / treatment of rabies / antibody‐based biosimilar products / manufacturing process / biopharmaceutical / pharmaceuticals / biopharmaceutical products / biosimilar product / synthesized pharmaceuticals / ‐quality biologic drug products / biosimilar antibody product / biologic products / biosimilar monoclonal antibody product / biosimilar products / manufacturing / drug products / / MedicalCondition spondylitis / rabies / rheumatoid arthritis / plaque psoriasis / psoriasis / influenza / psoriatic arthritis / seasonal/pandemic influenza / chronic inflammatory condition / patients chronic pain / severe diseases / Crohn’s disease / ulcerative colitis / chronic disease / diseases / inflammation / numerous diseases / / Organization New York University / Korean Ministry of Food and Drug Safety / U.S. Patent & Trademark Office / U.S. Food & Drug Administration / Patent Office / European Medicines Agency / U.S. Federal Trade Commission / U.S. Centers for Disease Control and Prevention / / Position leader / / Product Infliximab / Remicade / Complaint / Remsima / United States / Remsima® / / ProvinceOrState Pennsylvania / Massachusetts / / Technology antibodies / biopharmaceuticals / / SocialTag 
Microsoft Word - Janssen Complaint